

Edith A Nutescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3665031/publications.pdf>

Version: 2024-02-01

146
papers

4,248
citations

126907

33
h-index

128289

60
g-index

149
all docs

149
docs citations

149
times ranked

4747
citing authors

#	ARTICLE	IF	CITATIONS
1	Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. <i>Pharmacogenomics</i> , 2022, 23, 85-95.	1.3	1
2	Can clinical pharmacists utilize telehealth to double the safety and efficacy of oral anticoagulation while reducing health care costs and improving patient satisfaction in patients with atrial fibrillation?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 969-977.	1.0	0
3	Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12-year single health system-based cohort analysis. <i>EJHaem</i> , 2021, 2, 97-101.	1.0	0
4	Association between transportation barriers and anticoagulation control among an inner-city, low-income population: A prospective observational cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12605.	2.3	2
5	Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1343.	2.5	2
6	Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey. <i>Journal of Diabetes</i> , 2020, 12, 385-395.	1.8	13
7	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. <i>Journal of Cancer Survivorship</i> , 2020, 14, 294-304.	2.9	9
8	Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 67-75.	0.9	6
9	Immigration Status and Disparities in the Treatment of Cardiovascular Disease Risk Factors in the Hispanic Community Health Study/Study of Latinos (Visit 2, 2014-2017). <i>American Journal of Public Health</i> , 2020, 110, 1397-1404.	2.7	16
10	Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Adults in the United States, 2011-2016. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006215.	2.2	21
11	Why African Americans Say "No": A Study of Pharmacogenomic Research Participation. <i>Ethnicity and Disease</i> , 2020, 30, 159-166.	2.3	9
12	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
13	Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. <i>Pharmacotherapy</i> , 2019, 39, 921-928.	2.6	8
14	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner <i>et al</i> . <i>British Journal of Haematology</i> , 2019, 186, 782-783.	2.5	0
15	The ACCO-NT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. <i>Clinical and Translational Science</i> , 2019, 12, 209-217.	3.1	32
16	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study. <i>Pharmacotherapy</i> , 2019, 39, 55-66.	2.6	8
17	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1077-1089.	3.5	12
18	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. <i>British Journal of Haematology</i> , 2019, 185, 116-127.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population. <i>Pharmacotherapy</i> , 2018, 38, 205-216.	2.6	21
20	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	2.9	213
21	Outcomes of systematic anticoagulation management in pharmacist and nurse specialized clinics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2018, 1, 68-73.	1.0	2
22	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. <i>British Journal of Haematology</i> , 2018, 182, 259-270.	2.5	16
23	A New Approach towards Minimizing the Risk of Mis dosing Warfarin Initiation Doses. <i>Computational and Mathematical Methods in Medicine</i> , 2018, 2018, 1-11.	1.3	8
24	Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas. <i>Blood</i> , 2018, 132, 2280-2280.	1.4	8
25	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4693-4693.	1.4	0
26	Correlations between the enantio- and regio-selective metabolisms of warfarin. <i>Pharmacogenomics</i> , 2017, 18, 133-142.	1.3	0
27	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 435-441.	2.1	22
28	Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2017, 37, 1221-1230.	2.6	74
29	Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review. <i>Annals of Pharmacotherapy</i> , 2017, 51, 1122-1137.	1.9	61
30	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1944-1954.	1.0	34
31	Upper-Extremity Deep-Vein Thrombosis. <i>Annals of Pharmacotherapy</i> , 2016, 50, 637-644.	1.9	9
32	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 15-31.	2.1	108
33	Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy. <i>Thrombosis Research</i> , 2015, 135, 303-310.	1.7	57
34	Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. <i>Pharmacogenomics</i> , 2015, 16, 217-225.	1.3	14
35	Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 125-126.	1.9	0
36	Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. <i>Current Medical Research and Opinion</i> , 2015, 31, 439-447.	1.9	21

#	ARTICLE	IF	CITATIONS
37	Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 73-81.	1.5	79
38	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360.	2.8	92
39	Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1188-1194.	1.0	9
40	Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. <i>Journal of Medical Economics</i> , 2015, 18, 1041-1049.	2.1	2
41	Abstract W P302: Assessment of a New Method of Warfarin Management vs the New Oral Anticoagulants and Conventional Warfarin Management in Atrial Fibrillation. <i>Stroke</i> , 2015, 46, .	2.0	0
42	Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty in the United States: A Survey of Select American College of Clinical Pharmacy Practice and Research Network Members. <i>Pharmacotherapy</i> , 2014, 34, 1239-1249.	2.6	16
43	Cost-Effectiveness Analysis of Extended Duration Anticoagulation with Rivaroxaban to Prevent Recurrent Venous Thromboembolism. <i>Thrombosis Research</i> , 2014, 133, 743-749.	1.7	17
44	Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. <i>Journal of Medical Economics</i> , 2014, 17, 52-64.	2.1	62
45	Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice. <i>Thrombosis Research</i> , 2014, 134, 807-813.	1.7	14
46	Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service. <i>Pharmacotherapy</i> , 2013, 33, 1156-1164.	2.6	70
47	Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerations. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1914-1929.	1.0	49
48	Incidence of Venous Thromboembolism in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2013, 14, 578-584.	2.5	21
49	Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy. <i>Pharmacotherapy</i> , 2013, 33, 1223-1245.	2.6	18
50	Delivery of Optimized Inpatient Anticoagulation Therapy: Consensus Statement from the Anticoagulation Forum. <i>Annals of Pharmacotherapy</i> , 2013, 47, 714-724.	1.9	43
51	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. <i>Lancet</i> , The, 2013, 382, 790-796.	13.7	237
52	Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 525-534.	1.8	2
53	Personalized medicine in cardiology: the time for genotype-guided therapy is now. <i>Future Cardiology</i> , 2013, 9, 459-464.	1.2	1
54	Warfarin anticoagulation after total hip or total knee replacement: Clinical and resource-utilization outcomes in a university-based antithrombosis clinic. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 423-430.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Oral anticoagulant therapies: Balancing the risks. American Journal of Health-System Pharmacy, 2013, 70, S3-S11.	1.0	33
56	All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 1288-1297.	3.4	20
57	A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery. Current Orthopaedic Practice, 2012, 23, 221-228.	0.2	1
58	Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenetics and Genomics, 2012, 22, 152-158.	1.5	33
59	Apixaban: A novel oral inhibitor of factor Xa. American Journal of Health-System Pharmacy, 2012, 69, 1113-1126.	1.0	30
60	Use of Warfarin Therapy Among Residents Who Developed Venous Thromboembolism in the Nursing Home. American Journal of Geriatric Pharmacotherapy, 2012, 10, 361-372.	3.0	10
61	All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries. Journal of Managed Care Pharmacy, 2012, 18, 363-374.	2.2	40
62	Warfarin prophylaxis in patients after total knee or hip arthroplasty – international normalized ratio patterns and venous thromboembolism. Current Medical Research and Opinion, 2011, 27, 1973-1985.	1.9	12
63	Pharmacogenomics of Warfarin dose requirements in Hispanics. Blood Cells, Molecules, and Diseases, 2011, 46, 147-150.	1.4	36
64	Payment for Clinical Pharmacy Services Revisited. Pharmacotherapy, 2011, 31, 1-8.	2.6	22
65	Anticoagulation Patient Self-Monitoring in the United States: Considerations for Clinical Practice Adoption. Pharmacotherapy, 2011, 31, 1161-1174.	2.6	25
66	Dabigatran Etxilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness. Pharmacotherapy, 2011, 31, 1232-1249.	2.6	31
67	Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients. Pharmacotherapy, 2011, 31, 785-792.	2.6	18
68	Emerging Antiplatelet Therapies in Percutaneous Coronary Intervention: A Focus on Prasugrel. Clinical Therapeutics, 2011, 33, 425-442.	2.5	7
69	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. Journal of Thrombosis and Thrombolysis, 2011, 31, 326-343.	2.1	211
70	Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. Journal of Medical Economics, 2011, 14, 324-334.	2.1	14
71	Anticoagulation therapy for hospitalized patients: Patterns of use, compliance with national guidelines, and performance on quality measures. American Journal of Health-System Pharmacy, 2011, 68, 1239-1244.	1.0	15
72	Characteristics of novel anticoagulants and potential economic implications. American Journal of Managed Care, 2011, 17, S27-32.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Anticoagulation Management Services: Entering a New Era. <i>Pharmacotherapy</i> , 2010, 30, 327-329.	2.6	16
74	Changes in the USP Heparin Monograph and Implications for Clinicians. <i>Pharmacotherapy</i> , 2010, 30, 428-431.	2.6	13
75	Dosing guidelines, not protocols, for managing warfarin therapy. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1554-1556.	1.0	7
76	A Clinician's Guide to Perioperative Bridging for Patients on Oral Anticoagulation. <i>Journal of Pharmacy Practice</i> , 2010, 23, 303-312.	1.0	7
77	Thrombotic Risk and Immobility in Residents of Long-Term Care Facilities. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 211-221.	2.5	23
78	Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1265-1273.	1.0	38
79	Anticoagulation: Effect of a Warfarin Adherence Aid on Anticoagulation Control in an Inner-City Anticoagulation Clinic Population. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1165-1172.	1.9	19
80	Predictors of unstable anticoagulation in African Americans. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 430-437.	2.1	23
81	Influence of Cyclooxygenase-1 Genotype on ex vivo Aspirin Response in Patients at Risk for Stroke. <i>Cerebrovascular Diseases</i> , 2009, 27, 585-593.	1.7	4
82	Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1064-1083.	1.9	256
83	Warfarin INR Patterns Following Total Hip Arthroplasty.. <i>Blood</i> , 2009, 114, 1068-1068.	1.4	0
84	Warfarin INR Patterns Following Total Knee Arthroplasty.. <i>Blood</i> , 2009, 114, 2100-2100.	1.4	0
85	Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 248-250.	2.1	6
86	New Anticoagulant Agents: Direct Thrombin Inhibitors. <i>Cardiology Clinics</i> , 2008, 26, 169-187.	2.2	47
87	Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum. <i>Annals of Pharmacotherapy</i> , 2008, 42, 979-988.	1.9	88
88	Rivaroxaban: An oral direct inhibitor of factor Xa. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1520-1529.	1.0	79
89	Burden of Deep Vein Thrombosis in the Outpatient Setting Following Major Orthopedic Surgery. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1216-1221.	1.9	19
90	Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 95-105.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Quality of Oral Anticoagulation Management in Pharmacist Vs Nurse Managed Models of Care. <i>Blood</i> , 2008, 112, 4665-4665.	1.4	5
92	Differences among Various Low-Molecular-Weight Heparins in Patients with Severe Renal Insufficiency: An Analysis of Recent Clinical Trials. <i>Blood</i> , 2008, 112, 4047-4047.	1.4	0
93	Basic terminology in obtaining reimbursement for pharmacists's cognitive services. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 186-192.	1.0	18
94	ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 2281-2291.	1.0	4
95	Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, S5-S13.	1.0	39
96	Survey of hospitals for guidelines, policies, and protocols for anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 1203-1208.	1.0	22
97	Factors influencing warfarin dose requirements in African-Americans. <i>Pharmacogenomics</i> , 2007, 8, 1535-1544.	1.3	72
98	New Anticoagulant Agents: Direct Thrombin Inhibitors. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 33-56.	2.6	12
99	Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 101-110.	1.5	326
100	Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery. <i>Value in Health</i> , 2006, 9, 68-76.	0.3	19
101	Outcomes of Oral Anticoagulant Therapy Managed by Telephone vs In-Office Visits in an Anticoagulation Clinic Setting. <i>Chest</i> , 2006, 130, 1385-1389.	0.8	56
102	Sex Difference in the Antiplatelet Effect of Aspirin in Patients with Stroke. <i>Annals of Pharmacotherapy</i> , 2006, 40, 812-817.	1.9	27
103	Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1558-1571.	1.9	9
104	Warfarin and its interactions with foods, herbs and other dietary supplements. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 433-451.	2.4	122
105	Quality of Warfarin Management in Anticoagulation Clinics in the U.S.. <i>Blood</i> , 2006, 108, 627-627.	1.4	1
106	Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. <i>Thrombosis and Haemostasis</i> , 2006, 96, 137-41.	3.4	6
107	Drug evaluation: the directly activated Factor Xa inhibitor otamixaban. <i>IDrugs: the Investigational Drugs Journal</i> , 2006, 9, 854-65.	0.7	2
108	Anticoagulant agents are mainstay therapies in the prevention and treatment of arterial and venous thrombosis. Introduction. <i>American Journal of Managed Care</i> , 2006, 12, S427-9.	1.1	0

#	ARTICLE	IF	CITATIONS
109	Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies. <i>American Journal of Managed Care</i> , 2006, 12, S444-50.	1.1	1
110	Economic considerations in managing patients with chronic stable angina. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, S17-21.	2.2	0
111	Factors that influence prescribing within a therapeutic drug class. <i>Journal of Evaluation in Clinical Practice</i> , 2005, 11, 357-365.	1.8	12
112	Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 241-250.	0.9	5
113	Current and emerging treatment options for venous thrombosis: A case discussion. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 593-605.	1.0	0
114	Anticoagulation Monitoring Part 1: Warfarin and Parenteral Direct Thrombin Inhibitors. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1049-1055.	1.9	15
115	Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1275-1285.	1.9	68
116	A pharmacologic overview of current and emerging anticoagulants.. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, S2-S2.	1.3	51
117	Strategies for Cost-Effective Prevention and Treatment of Venous Thromboembolism: Introduction. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, S3-S4.	1.0	2
118	Emerging Options in The Treatment of Venous Thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, S12-S17.	1.0	8
119	Point of Care Monitors for Oral Anticoagulant Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 697-702.	2.7	10
120	Generic Warfarin: Implications for Clinical Practice and Perceptions of Anticoagulation Providers. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 619-626.	2.7	13
121	Direct Thrombin Inhibitors for Anticoagulation. <i>Annals of Pharmacotherapy</i> , 2004, 38, 99-109.	1.9	53
122	Ximelagatran: An Oral Direct Thrombin Inhibitor. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1881-1897.	1.9	13
123	Factors that Influence Prescribing Decisions. <i>Annals of Pharmacotherapy</i> , 2004, 38, 557-562.	1.9	90
124	Impact of Prescribing Guidelines for Inpatient Anticoagulation. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1570-1575.	1.9	11
125	Introductionâ€“Current Concepts in Thrombosis Management: Focus on Factor Xa Inhibition. <i>Pharmacotherapy</i> , 2004, 24, 61S-61S.	2.6	0
126	Evolving Concepts in the Treatment of Venous Thromboembolism: The Role of Factor Xa Inhibitors. <i>Pharmacotherapy</i> , 2004, 24, 82S-87S.	2.6	3

#	ARTICLE	IF	CITATIONS
127	Special Considerations with Fondaparinux Therapy: Heparin-Induced Thrombocytopenia and Wound Healing. <i>Pharmacotherapy</i> , 2004, 24, 88S-94S.	2.6	23
128	Treatment of Venous Thromboembolism: Challenging the Unfractionated Heparin Standard. <i>Pharmacotherapy</i> , 2004, 24, 127S-131S.	2.6	3
129	Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Clinics. <i>Pharmacotherapy</i> , 2004, 24, 1204-1212.	2.6	5
130	New Developments in Anticoagulation Therapy: Oral Direct Thrombin Inhibitors. <i>Pharmacotherapy</i> , 2004, 24, 165S-165S.	2.6	0
131	Transitioning from Traditional to Novel Anticoagulants: The Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Management. <i>Pharmacotherapy</i> , 2004, 24, 199S-202S.	2.6	11
132	Oral Anticoagulation: Preparing for Change. <i>Journal of the American Medical Directors Association</i> , 2004, 5, 2-10.	2.5	6
133	New Blood Thinner Offers First Potential Alternative in 50 Years. <i>Journal of Cardiovascular Nursing</i> , 2004, 19, 374-383.	1.1	5
134	Oral anticoagulation: preparing for change. <i>Journal of the American Medical Directors Association</i> , 2004, 5, 2-11.	2.5	1
135	The Future of Anticoagulation Clinics. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 61-63.	2.1	18
136	Ezetimibe: A Selective Cholesterol Absorption Inhibitor. <i>Pharmacotherapy</i> , 2003, 23, 1463-1474.	2.6	81
137	Hospital Guidelines for Use of Low-Molecular-Weight Heparins. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1072-1081.	1.9	6
138	Tinzaparin: Considerations for Use in Clinical Practice. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1831-1840.	1.9	7
139	Wound Pharmacobiology. <i>Orthopedics</i> , 2003, 26, .	1.1	3
140	Wound pharmacobiology. <i>Orthopedics</i> , 2003, 26, s837-42.	1.1	1
141	Antithrombotic therapy for the treatment of venous thromboembolism. <i>American Journal of Managed Care</i> , 2003, 9, S103-14; quiz S115-20.	1.1	2
142	Survey of hospital policies regarding low-molecular-weight heparins. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 534-538.	1.0	12
143	Traditional versus modern anticoagulant strategies: Summary of the literature. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, S7-S14.	1.0	12
144	Dosing and Monitoring of Low-Molecular-Weight Heparins in Special Populations. <i>Pharmacotherapy</i> , 2001, 21, 218-234.	2.6	127

#	ARTICLE	IF	CITATIONS
145	Warfarin-Acetaminophen Drug Interaction Revisited. <i>Pharmacotherapy</i> , 1999, 19, 1153-1158.	2.6	26
146	Multidisciplinary approach to improving allergy documentation. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 364-368.	1.0	3